CROMA-PHARMA GmbH

🇦🇹Austria

Country: 🇦🇹Austria

Ownership: Private

Established: 1976-01-01

Employees: 251

Market Cap: -

Website: http://www.croma.at

Clinical Trials

THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick Lips

Not Applicable

Completed

Conditions: Lip Abnormality

Interventions: Device: Thioderm Elate
Device: Juvéderm Ultra 3

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-13

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 33

Registration Number: NCT06135337

Locations: 🇦🇹
H&P Ambulatorien GmbH, Vienna, Austria

THIODERM ELATE for Volume Augmentation in Lips

Not Applicable

Withdrawn

Conditions: Lip; Anomaly

Interventions: Device: THIODERM ELATE
Device: Juvéderm Ultra 3

First Posted Date: 2023-11-15

Last Posted Date: 2024-12-11

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 266

Registration Number: NCT06133153

Locations: 🇦🇹
H&P Ambulatorien GmbH, Vienna, Austria

THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit

Not Applicable

Completed

Conditions: Mid Face Volume Deficit

Interventions: Device: Thioderm Strong
Device: Juvéderm VOLUMA Lidocaine

First Posted Date: 2023-11-13

Last Posted Date: 2024-12-12

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 20

Registration Number: NCT06128109

Locations: 🇦🇹
H&P Ambulatorien GmbH, Vienna, Austria

Saypha® VOLUME Lidocaine for Midface Augmentation

Phase 3

Active, not recruiting

Conditions: Moderate to Severe Midface Volume Deficit

Interventions: Combination Product: Juvéderm® Voluma™ XC
Combination Product: saypha® VOLUME Lidocaine

First Posted Date: 2022-05-23

Last Posted Date: 2023-04-14

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 486

Registration Number: NCT05386030

Locations: 🇺🇸
Meridian Clinical Research, Georgia Plastic Surgery, Savannah, Georgia, United States
🇺🇸
Chicago Cosmetic, Chicago, Illinois, United States
🇺🇸
DermResearchCenter of NY, Stony Brook, New York, United States

and more 13 locations

Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation

Phase 3

Completed

Conditions: Abnormal Lip

Interventions: Combination Product: Saypha® FILLER Lidocaine (HQ)
Combination Product: Saypha® FILLER Lidocaine (C1)

First Posted Date: 2021-06-08

Last Posted Date: 2022-05-16

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 114

Registration Number: NCT04917588

Locations: 🇦🇹
Dr. Doris Grablowitz, Vienna, Austria
🇦🇹
YUVELL® Fine Aesthetics, Vienna, Austria
🇦🇹
PW-Privatklinik Währing GmbH, Vienna, Austria

SAVINO (Saypha® Volume LIdocaine in Nasolabial FOlds)

Not Applicable

Completed

Conditions: Moderate to Severe Nasolabial Folds

Interventions: Combination Product: Saypha Volume Lidocaine

First Posted Date: 2021-05-12

Last Posted Date: 2022-07-20

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 110

Registration Number: NCT04883632

Locations: 🇦🇹
Dr. Worseg, Vienna, Austria
🇦🇹
Dr. Gaerner, Vienna, Austria
🇦🇹
Yuvell, Vienna, Austria

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Phase 2

Completed

Conditions: Frown Lines

Interventions: Biological: Botulinum toxin A "BoNT/A-DP"
Biological: Botulinum toxin A "Botox Cosmetics"

First Posted Date: 2021-02-21

Last Posted Date: 2021-02-21

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 200

Registration Number: NCT04763265

Locations: 🇨🇦
Sweat Clinics of Canada, Toronto, Ontario, Canada
🇺🇸
Skin Research Institute LLC, Coral Gables, Florida, United States
🇺🇸
ATS Clinical Research, Santa Monica, California, United States

and more 2 locations

Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

Not Applicable

Completed

Conditions: Dermatological Non-Disease

Interventions: Device: Princess Filler Lidocaine

First Posted Date: 2019-06-19

Last Posted Date: 2022-03-22

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 295

Registration Number: NCT03990883

Locations: 🇺🇸
Sabrina Fabi, San Diego, California, United States
🇺🇸
Gary Monheit, Birmingham, Alabama, United States
🇺🇸
John Joseph, Beverly Hills, California, United States

and more 8 locations

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

Phase 3

Completed

Conditions: Glabellar Frown Lines

Interventions: Drug: Botulinum Toxin A
Drug: Placebo

First Posted Date: 2019-06-14

Last Posted Date: 2021-05-19

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 355

Registration Number: NCT03985982

Locations: 🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States

Princess® RICH for the Correction of Fine Lines

Not Applicable

Completed

Conditions: Lateral Canthal Lines
Perioral Rhytids

Interventions: Device: Princess® RICH

First Posted Date: 2019-04-22

Last Posted Date: 2024-12-10

Lead Sponsor: Croma-Pharma GmbH

Target Recruit Count: 102

Registration Number: NCT03923634

Locations: 🇦🇹
MaRa-Medical Aesthetic Research Academy, Graz, Austria
🇦🇹
YUVELL, Vienna, Austria
🇦🇹
Medizinische Universität-Klinikum für Dermatologie und Venerologie, Graz, Austria

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy